BioSpace News Archive

According to Latest Report Study, the global nuclear medicine market size was accounted at USD 8.5 billion in 2021 and is expected to hit around USD 25 billion by 2030, expanding growth at a CAGR 13.2% from 2022 to 2030.

The global molecular diagnostics market size is expected to reach around US$ 59.3 billion by 2030, according to a new report by Vision Research Reports.

The global in-vitro toxicology assays market size is expected to be worth around US$ 4.9 billion by 2030, according to a new report by Vision Research Reports.

The global antibody drug conjugates market size is expected to be worth around US$ 10.93 billion by 2030, according to a new report by Vision Research Reports.

The global high potency active pharmaceutical ingredients market size is expected to be worth around US$ 44.8 billion by 2030, according to a new report by Vision Research Reports.

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, announced that Jin-Chen Yu, SVP, Research will present a talk on BAT8009 at the 2nd Annual ADC Target Selection Summit taking place December 6 - 8, 2022 in Boston, MA.

SciNeuro Pharmaceuticals is developing novel therapeutics to address major unmet need within CNS diseases. The company is pleased to announce an executive leadership appointment, and update on key pipeline progress milestones.

Walden Biosciences, Inc. today announced that Alex Duncan, Ph.D., Chief Scientific Officer of Walden Biosciences, will give a presentation at the Antibody Engineering and Therapeutic Conference 2022, being held from December 4-8, 2022 in San Diego, CA.

STRATA Skin Sciences, Inc. announced the company will present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference being held at the Fontainebleau Miami Beach, Miami, Florida on December 8, 2022.

Reaction Biology Corporation (“Reaction”) today announced that the Company has closed on a definitive agreement for Reaction to acquire Bioassay Labor für biologische Analytik GmbH (“Bioassay”), including its wholly-owned subsidiary, Peptide Specialty Laboratories GmbH (“PSL”), located in Heidelberg, Germany.